Certified ISO 9001 : 2015 by

BVQi UKAS QUALITY MANAGEMENT

Sakar
Healthcare Limited

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

24th July, 2026

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Symbol: SAKAR

Dear Sir,

Sub: Outcome of the Board Meeting held on 24th July, 2026

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Outcome of the Board Meeting held today, i.e., 24th July, 2026, along with the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026, together with the Limited Review Report and other applicable disclosures.

The same is enclosed herewith for your kind information and record.

Thanking you,

Yours faithfully,
for SAKAR HEALTHCARE LIMITED
BHARATKUMAR SUKHLAL SONI
Digitally signed by BHARATKUMAR SUKHLAL SONI
Date: 2026.07.24 12:07:47 +05'30'
BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER

Sakar
Healthcare Limited

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

24th July, 2026

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051

Symbol: SAKAR

Dear Sir,

Sub: Outcome of Board Meeting - Submission of Un-Audited Financial Results for the quarter ended on 30th June, 2026, intimation of date of Annual General Meeting, e-voting period & other matters

We refer to our letter dated 20th July, 2026 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors of the Company ('the Board'), in their meeting held today, *inter alia,* have taken on record the Unaudited Financial Results for the quarter ended on 30th June, 2026.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith the Statement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on 30th June, 2026 – Integrated Filing (Financial) along with Auditors' Limited Review Report thereon as **Annexure – 1.**

Further, the Board of Directors of the Company in their meeting held today, *inter alia*, has also decided to:

1. Convene the 22nd Annual General Meeting ('AGM') of the Shareholders/Members of the Company on Tuesday, the 22nd September, 2026 at 12:30 p.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') in compliance with the applicable provisions of the Companies Act, 2013 read with General Circular No. 03/2025 dated 22nd September, 2025 & the requirements laid down in Para 3 and Para 4 of the General Circular No.20/2020 dated 5th May, 2020 and earlier circulars issued by the Ministry of Corporate Affairs in this regard ('MCA circulars') and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. provide to its Shareholders, the facility to cast their vote by electronic means i.e. 'Remote e-voting' and 'e-voting system during the AGM' on all the resolution set forth in the Notice of 22nd AGM. The details of 'Remote e-voting' are given under:

1	Date & Time of commencement of Remote e-voting	at 9:00 a.m. on 19th September, 2026
2	Date & Time of end of Remote e-voting	at 5:00 p.m. on 21st September, 2026
3	Cut-off date for determining rights of entitlement of Remote e-voting	15th September, 2026
4	E-voting system during the AGM shall not be allowed beyond	15 Minutes after the conclusion of AGM

SAKAR HEALTHCARE LTD.

The Board, in their meeting held today, also considered and approved:

a) appointment of M/s. Kashyap R. Mehta & Partners, Practising Company Secretaries, (FRN: P2025GJ106000 and Peer Reviewed Certificate No. 6827/2025), as Secretarial Auditors of the Company for a term of five (5) consecutive years commencing from financial year 2026-27 to 2030-31, subject to shareholders' approval at ensuing 22nd AGM of the Company.

b) appointment of M/s. Dalwadi & Associates, Cost Accountants, Ahmedabad Firm Registration No. 000338), as Cost Auditors of the Company for the financial year 2026-27.

The necessary disclosures under Regulation 30 of Listing Regulations is as per **Annexure – 2.**

The Meeting of the Board of Directors was commenced at 11:30 a.m. and concluded at 12:00 NOON.

This is in due compliance of the relevant Regulations of the SEBI (LODR) Regulations, 2015.

Yours faithfully,

FOR SAKAR HEALTHCARE LIMITED

SANJAY S. SHAH
MANAGING DIRECTOR
DIN: 01515296

SAKAR HEALTHCARE LTD.

Encl: As Above

Sakar
Healthcare Ltd.
[CIN: L24231GJ2004PLC043861]
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad _382 213
Phone: 02717-250477 Fax: 02717-251621 Email: info@ sakarhealthcare.com Web: www.sakarhealthcare.com

STATEMENT OF STANDALONE UNAUDITED FINACIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. In Lakh)

	Particulars	Quarter ended on			Previous Year ended on
	(Refer Notes Below)	30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	7297.25	7109.70	5273.62	25173.60
2	Other income	154.39	17.12	39.39	228.74
3	**Total Income (1+2)**	**7451.64**	**7126.82**	**5313.01**	**25402.34**
4	Expenses				
	a. Cost of Materials consumed	4003.52	3577.85	2875.73	13268.83
	b. Purchases of stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(545.30)	(739.76)	19.51	(941.16)
	d. Employee benefits expense	1145.51	1293.80	754.96	3871.69
	e. Finance costs	166.97	241.12	214.26	785.59
	f. Depreciation & amortisation expense	654.24	593.57	557.23	2356.45
	g. Other expenses	568.63	354.24	352.84	2085.42
	Total Expenses	**5993.57**	**5320.82**	**4774.53**	**21426.82**
5	Profit before exceptional items and tax (3-4)	1458.07	1806.00	538.48	3975.52
6	Exceptional items	-	-	-	-
7	**Profit before tax (5-6)**	**1458.07**	**1806.00**	**538.48**	**3975.52**
8	Tax expense:				
	Current tax	393.42	301.44	90.29	675.68
	Deferred tax	36.16	80.62	71.35	304.11
	MAT Credit Entitlement	-	321.51	(90.29)	(52.73)
9	**Profit for the period from continuing operations (7-8)**	**1028.49**	**1102.43**	**467.13**	**3048.46**
10	Profit from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	**Profit for the period (9+12)**	**1028.49**	**1102.43**	**467.13**	**3048.46**

SAKAR HEALTHCARE LTD.

Sakar Healthcare Ltd.
[CIN: L24231GJ2004PLC043861**]**
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213
Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

(Rs. In Lakh)

	Particulars	Quarter ended on			Previous Year ended on 31-03-2026
	(Refer Notes Below)	30-06-2026 (Unaudited)	31-03-2026 (Audited)	30-06-2025 (Unaudited)	(Audited)
14	**Other Comprehensive Income**				
	Items that will not be reclassified subsequently to profit or loss				
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(3.70)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	1.03	4.12
	Items that will be reclassified subsequently to profit or loss				
	Income tax relating to items that will be reclassified to profit or loss				
	Other Comprehensive Income, net of tax	**(2.67)**	**(2.67)**	**(2.67)**	**(10.68)**
15	**Total Comprehensive Income for the period (13+14)**	**1025.82**	**1099.76**	**464.46**	**3037.77**
16	Paid-up equity shares capital (Face Value per share Rs.10/-)	2224.99	2224.99	2224.99	2224.99
17	Reserves excluding Revaluation Reserves				30228.78
18	Earnings Per Share of Rs. 10/- each (for continuing operations)				
	- Basic	4.62	4.96	2.11	13.70
	- Diluted	4.62	4.96	2.11	13.70
19	Earnings Per Share of Rs.10/- each (for discontinued operations)				
	- Basic	-	-	-	-
	- Diluted	-	-	-	-
20	Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)				
	- Basic	4.62	4.96	2.11	13.70
	- Diluted	4.62	4.96	2.11	13.70

FOR SAKAR HEALTHCARE LIMITED

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 24th July, 2026
Place: Ahmedabad

Sakar
Healthcare Ltd.
[CIN: L24231GJ2004PLC043861]
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213
Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@ sakarhealthcare.com **Web:** www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment i.e. Manufacturing of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 24th July 2026
7	The figures for quarter ended on 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2026 and the year to date figures upto the third quarter of the financial year.

FOR SAKAR HEALTHCARE LIMITED

Sanjay

SAKAR HEALTHCARE LTD.

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 24th July, 2026
Place: Ahmedabad

LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED JUNE 30, 2026

To
The Board of Directors
M/s. Sakar Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period quarter ended **30th June 2026**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
FRN : 132059W

J. S. SHAH & CO. AHMEDABAD 380028 CHARTERED ACCOUNTANTS

Jaimin S Shah
Partner
Membership No. : 138488
UDIN : 26138488SWUMDC5099

Place : Ahmedabad
Date : 24.07.2026

Sakar
Healthcare Ltd.
[CIN: L24231GJ2004PLC043861]
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213
Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@ sakarhealthcare.com **Web:** www.sakarhealthcare.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. In lakh)

	Particulars	Quarter ended on			Previous Year ended on
	(Refer Notes Below)	30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	7297.25	7109.70	5273.62	25173.60
2	Other income	154.39	17.12	39.39	228.74
3	**Total Income (1+2)**	**7451.64**	**7126.82**	**5313.01**	**25402.34**
4	Expenses				
	a. Cost of Materials consumed	4003.52	3577.85	2875.73	13268.83
	b. Purchases of stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(545.30)	(739.76)	19.51	(941.16)
	d. Employee benefits expense	1145.51	1293.80	754.96	3871.69
	e. Finance costs	166.97	241.12	214.26	785.59
	f. Depreciation & amortisation expense	654.24	593.57	557.23	2356.45
	g. Other expenses	568.63	354.24	352.84	2085.42
	Total Expenses	**5993.57**	**5320.82**	**4774.53**	**21426.82**
5	Profit before exceptional items and tax (3-4)	1458.07	1806.00	538.48	3975.52
6	Exceptional items	-	-	-	-
7	**Profit before tax (5-6)**	**1458.07**	**1806.00**	**538.48**	**3975.52**
8	Tax expense:				
	Current tax	393.42	301.44	90.29	675.68
	Deferred tax	36.16	80.62	71.35	304.11
	MAT Credit Entitlement	-	321.51	(90.29)	(52.73)
9	**Profit for the period from continuing operations (7-8)**	**1028.49**	**1102.43**	**467.13**	**3048.46**
10	Profit from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	**Profit for the period (9+12)**	**1028.49**	**1102.43**	**467.13**	**3048.46**
	Attributable to owner of parent	1028.49	1102.43	467.13	3048.46
	Attributable to Non-controlling interests	-	-	-	-

SAKAR HEALTHCARE LTD. *

Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007
Phone: 079-26584655 **Fax:** 079-26588054

Sakar
Healthcare Ltd.
[CIN: L24231GJ2004PLC043861]
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213
Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

(Rs. In lakh)

	Particulars	Quarter ended on			Previous Year ended on 31-03-2026
	(Refer Notes Below)	30-06-2026	31-03-2026	30-06-2025	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
14	**Other Comprehensive Income**				
	Items that will not be reclassified subsequently to profit or loss				
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(3.70)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	1.03	4.12
	Items that will be reclassified subsequently to profit or loss				
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other Comprehensive Income, net of tax	**(2.67)**	**(2.67)**	**(2.67)**	**(10.68)**
	Attributable to owner of parent	(2.67)	(2.67)	(2.67)	(10.68)
	Attributable to Non-controlling interests				
15	**Total Comprehensive Income for the period (13+14)**	**1025.82**	**1099.76**	**464.46**	**3037.77**
	Attributable to owner of parent	1025.82	1099.76	464.46	3037.77
	Attributable to Non-controlling interests	-	-	-	-
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	2224.99	2224.99	2224.99
17	Reserves excluding Revaluation Reserves				30220.26
18	Earnings Per Share of Rs.10/- each (for continuing operations)				
	- Basic	4.62	4.96	2.11	13.70
	- Diluted	4.62	4.96	2.11	13.70
19	Earnings Per Share of Rs.10/- each (for discontinued operations)				
	- Basic	-	-	-	-
	- Diluted	-	-	-	-
20	Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)				
	- Basic	4.62	4.96	2.11	13.70
	- Diluted	4.62	4.96	2.11	13.70

FOR SAKAR HEALTHCARE LIMITED

SA KAR HEALTHCARE LTD.

Sanjay

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 24th July, 2026
Place: Ahmedabad

Sakar
Healthcare Ltd.
[CIN: L24231GJ2004PLC043861]
Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213
Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment i.e. Manufacturing of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
2	The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
3	The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 24th July 2026
7	Further, the figures of Standalone and Consolidated Financial Results are identical since the subsidiary company has not carried out any business transactions during the relevant reporting period. Accordingly, there is no impact on the consolidated financial statements, resulting in the same figures as the standalone financials.
8	The figures for quarter ended on 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2026 and the year to date figures upto the third quarter of the financial year.

FOR SAKAR HEALTHCARE LIMITED

SAKAR HEALTHCARE LTD.

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 24th July, 2026
Place: Ahmedabad

LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED JUNE 30, 2026

To
The Board of Directors
M/s. Sakar Healthcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended **30th June 2026** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30.06.2026, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

   1) Sakar Oncology Private Limited

J. S. SHAH & CO. AHMEDABAD 380028 CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
FRN : 132059W

J. S. SHAH & CO. AHMEDABAD 380028 CHARTERED ACCOUNTANTS

Jaimin S Shah
Partner
Membership No. : 138488
UDIN : 26138488EGPROY8112

Place : Ahmedabad
Date : 24.07.2026

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable

C. DISCLOSURE OF OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

Not Applicable

Sr. No.	Particulars	in INR crore
1.	**Loans / revolving facilities like cash credit from banks / financial institutions**	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
2.	**Unlisted debt securities i.e. NCDs and NCRPS**	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
3.	**Total financial indebtedness of the listed entity including short-term and long-term debt**	0

D. DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED (applicable only for half-yearly filings i.e., 2nd and 4th quarter) :

Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

Not Applicable

FOR SAKAR HEALTHCARE LIMITED

SAKAR HEALTHCARE LTD.

Date: 24th July, 2026
Place: Ahmedabad

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Annexure-2

The disclosure with regard to appointment of Secretarial Auditor:

Sr. No.	Disclosure requirement	Details of Secretarial Auditor
(a)	Name of Auditors	M/s. Kashyap R. Mehta & Partners, Practising Company Secretaries
(b)	Reason for change	Appointment
(c)	Date of recommendation & Terms for Appointment	Date of Appointment: 24th July, 2026 Terms of Appointment: Board of Directors in its meeting held on 24th July, 2026 appointed M/s. Kashyap R. Mehta & Partners, Practising Company Secretaries as Secretarial Auditors of the Company for a term of five (5) consecutive years to conduct the Secretarial Audit for financial years commencing from FY 2026-27 to FY 2030-31 subject to approval of shareholders/members at the ensuing AGM.
(d)	Brief Profile	Kashyap R. Mehta & Partners ('the Firm') is a partnership of Practising Company Secretaries based in Ahmedabad (Gujarat, India) delivering integrated legal & advisory services in the fields of Corporate & Allied Laws, Capital Markets and Corporate Governance. Mr. Kashyap Mehta, a lead partner of the firm has a distinguished track record extending over four decades with the team and other partner being led by a senior professional of considerable repute, possessing extensive experience in providing services to both listed and unlisted clients. They offer a full spectrum of corporate, secretarial, regulatory, compliance services, and legal & regulatory services relating to various Corporate Laws and SEBI Laws and stock exchange related matters.
(e)	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable

The disclosure with regard to appointment of Cost Auditor:

Sr. No.	Disclosure requirement	Details of Cost Auditor
(a)	Name of Auditors	M/s Dalwadi & Associates, Cost Accountants
(b)	Reason for change	Appointment / Re- appointment
(c)	Date & Terms of Appointment	24th July, 2026 Appointment as Cost Auditors of the Company for the F.Y. 2026-27
(d)	Brief Profile	M/s Dalwadi & Associates, Cost Accountants having qualified Cost & Management Accountants rendering services encompassing, services of Audit & Assurance, Indirect Taxes, Management Advisory Services, Finance & Banking, etc. The partners of the firm have exposure of more than one decade in the field of Cost & Management Accountancy.
(e)	Disclosure of relationships between Directors (in case of appointment of a director)	None

FOR SAKAR HEALTHCARE LIMITED

SAKAR HEALTHCARE LTD.

SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 24th July, 2026
Place: Ahmedabad